Influence of an acidic beverage on the absorption of erlotinib

Phase 4

Completed

• Conditions: lung cancer; 10038666

• Registration Number: NL-OMON40431
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 28

Inclusion Criteria

1. Age >= 18 years
2. Use of Erlotinib monotherapy for at least 4 weeks
3. Subject is able and willing to sign the Informed Consent Form prior to screening evaluations

Exclusion Criteria

1. Age < 18 years
2. Pregnant or lactating patients
3. Impossibility to take oral drugs

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Differences in erlotinib bioavailability during coca-cola intake vs. water<br /><br>intake.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>To compare the incidence and severity of side-effects of treatment with<br /><br>erlotinib in absence and presence of Coca-Cola.</p><br>